Loading…
Taysha Gene Therapies, Inc. is projected to rise to $6.64 by 2027, a +16% move from its current price of $5.75. TSHA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $5.55 | $5.75 | $5.97 | +0.08% |
| May 30 | $5.47 | $5.76 | $6.06 | +0.15% |
| May 31 | $5.41 | $5.76 | $6.14 | +0.23% |
| Jun 1 | $5.36 | $5.77 | $6.21 | +0.30% |
| Jun 2 | $5.32 | $5.77 | $6.26 | +0.38% |
| Jun 3 | $5.28 | $5.78 | $6.32 | +0.46% |
| Jun 4 | $5.25 | $5.78 | $6.37 | +0.53% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.25 | $5.78 | $6.37 | +0.53% |
| Week 2 | $5.07 | $5.81 | $6.66 | +1.07% |
| Week 3 | $4.94 | $5.84 | $6.91 | +1.61% |
| Week 4 | $4.84 | $5.87 | $7.13 | +2.15% |
| Week 5 | $4.76 | $5.90 | $7.33 | +2.69% |
| Week 6 | $4.68 | $5.94 | $7.52 | +3.24% |
| Week 7 | $4.62 | $5.97 | $7.71 | +3.79% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company lists TSHA-120 for giant axonal neuropathy, TSHA-102 for Rett syndrome, TSHA-121 for CLN7 disease, TSHA-118 for CLN1 disease, TSHA-105 for SLC13A5 deficiency, TSHA-113 for tauopathies, TSHA-106 for angelman syndrome, and TSHA-114 for fragile X syndrome as part of its program slate.
The business operates in the healthcare category and collaborates with The University of Texas Southwestern Medical Center on research, collaboration, and license agreements.
Taysha Gene Therapies was incorporated in 2019 and is headquartered in Dallas, Texas.
The asset, Taysha Gene Therapies, Inc. (TSHA), is currently priced at $5.49 per share with a market capitalization of $1.58B and a listed rank of 2189. The stock trades within a 30-day window and faces near-term technical levels that frame its price action.
Longer-term projections show substantial upside under the provided forecast, with average prices rising across multiple years and sizable ROI potential, culminating in multifold gains by 2050. The outlook depicts a transition from a neutral near term to a bullish multi-year trajectory, supported by higher expected average prices in successive years.
A major floor 29.2% below — a decisive break under it would weaken the trend.
The nearest floor, 9.8% below — buyers have tended to step in here.
The nearest ceiling, 21.4% above — a clean break opens room to run.
A major ceiling 35.1% above — clearing it would confirm fresh momentum.
Key TSHA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TSHA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.57 | Buy | $5.64 | Buy |
| MA 10 | $5.74 | Buy | $5.78 | Sell |
| MA 20 | $6.21 | Sell | $5.92 | Sell |
| MA 50 | $5.53 | Buy | $5.67 | Buy |
| MA 100 | $5.12 | Buy | $5.28 | Buy |
| MA 200 | $4.65 | Buy | $4.66 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.10 | Neutral |
| Stoch RSI (14) | 37.97 | Neutral |
| CCI (20) | -58.48 | Neutral |
| Williams %R (14) | -66.07 | Info |
| MACD (12,26,9) | -0.15 | Sell |
| ROC (12) | -15.57 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 33.93 | Neutral |
| TRIX (15) | 0.25 | Buy |
| Awesome (5,34) | -0.48 | Sell |
| Ultimate (7,14,28) | 39.34 | Neutral |
| Momentum (10) | -1.10 | Sell |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 5.56 | Buy |
| ADX (14) | 22.08 | Sell |
| ATR (14) | 0.19 | Info |
RSI14 stands at 40, suggesting room to move higher before overbought conditions arise, and the near-term tone remains constructive.
Key moving averages indicate the stock trading near the SMA50 of $5.48 while the SMA200 sits at $4.63. Support is identified at $4.42 and resistance at $6.98. The 30-day price range spans from $4.27 to $7.07, and annualized volatility is about 70%, underscoring notable movement potential in the month ahead.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.07 | $5.75 | $7.88 | 0% | Neutral | |
| $5.10 | $6.64 | $9.27 | +16% | Neutral | |
| $5.33 | $7.22 | $10.54 | +26% | Bullish | |
| $6.43 | $8.99 | $13.61 | +56% | Bullish | |
| $7.96 | $11.46 | $17.87 | +99% | Bullish | |
| $8.79 | $12.99 | $20.80 | +126% | Bullish | |
| $9.50 | $14.38 | $23.57 | +150% | Bullish | |
| $9.50 | $14.73 | $24.66 | +156% | Bullish | |
| $9.86 | $15.62 | $26.66 | +172% | Bullish | |
| $10.19 | $16.51 | $28.68 | +187% | Bullish | |
| $16.00 | $28.65 | $53.65 | +398% | Bullish | |
| $29.83 | $64.08 | $133.60 | +10.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $4.07 | $5.75 | $6.76 | +0.00% |
| June 2026 | $4.95 | $5.85 | $7.12 | +1.82% |
| July 2026 | $5.15 | $6.16 | $7.63 | +5.26% |
| August 2026 | $5.11 | $6.17 | $7.74 | +0.09% |
| September 2026 | $5.01 | $6.09 | $7.73 | -1.28% |
| October 2026 | $5.13 | $6.28 | $8.05 | +3.10% |
| November 2026 | $5.14 | $6.34 | $8.20 | +0.95% |
| December 2026 | $4.87 | $6.04 | $7.88 | -4.70% |
Click any year to see its month-by-month TSHA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, TSHA could reach as high as $7.88, with a base case around $5.75 and support toward $4.07 — roughly 0% from $5.75. A consolidation phase looks the most probable path here.
Expect TSHA to range from $5.10 to $9.27 through 2027. The $6.64 average target implies a +16% move from current prices. That is up +16% on the projected 2026 average. Price action looks broadly range-bound.
The TSHA price prediction for 2028 points to an average of $7.22 (low $5.33, high $10.54) — a potential gain of +26% on today's $5.75. Buyers look set to stay in control over this stretch.
In 2029, TSHA is projected to trade between $6.43 and $13.61, averaging $8.99 — a potential gain of +56% from today's $5.75. That is up +25% on the projected 2028 average. Momentum favours further upside here.
Taysha Gene Therapies, Inc.'s 2030 outlook centres on $11.46, within a $7.96 to $17.87 range. That is up +27% on the projected 2029 average. That marks a +99% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, TSHA could reach as high as $20.80, with a base case around $12.99 and support toward $8.79 — roughly +126% from $5.75. Momentum favours further upside here.
Expect TSHA to range from $9.50 to $23.57 through 2032. The $14.38 average target implies a +150% move from current prices. That is up +11% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The TSHA price prediction for 2033 points to an average of $14.73 (low $9.50, high $24.66) — a potential gain of +156% on today's $5.75. Momentum favours further upside here.
In 2034, TSHA is projected to trade between $9.86 and $26.66, averaging $15.62 — a potential gain of +172% from today's $5.75. That is up +6% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Taysha Gene Therapies, Inc.'s 2035 outlook centres on $16.51, within a $10.19 to $28.68 range. That is up +6% on the projected 2034 average. That marks a +187% change versus current levels. Momentum favours further upside here.
By 2040, TSHA could reach as high as $53.65, with a base case around $28.65 and support toward $16.00 — roughly +398% from $5.75. Buyers look set to stay in control over this stretch.
Expect TSHA to range from $29.83 to $133.60 through 2050. The $64.08 average target implies a +10.1x move from current prices. That is up +124% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in TSHA today (≈ 173.913043 TSHA) could be worth
$11,145.15
+$10,145.15 (+1015%) by 2050 · US Dollar
Based on the average projected TSHA price of $64.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TSHAwould be worth at today's price.
$1,000 invested in TSHA on May 27, 2025 (≈ 383.877156 TSHA) would be worth
$2,207.29
+$1,207.29 (+120.7%) today · 2.21× · US Dollar
Based on a TSHA entry price of $2.61 vs. today's $5.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.49 | $1,047.36 | +4.7% |
| 1 month ago | $6.46 | $890.09 | -11.0% |
| 3 months ago | $4.57 | $1,258.21 | +25.8% |
| 6 months ago | $4.74 | $1,213.08 | +21.3% |
| 1 year ago | $2.61 | $2,207.29 | +120.7% |
| All time (5.0y) ago | $22.2 | $259.01 | -74.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TSHA forecast.
Our base-case forecast reaches $12.00 around 2031.
Implied market cap at $12.00: $3.45B
The multi-year forecast shows a clear uptrend with bullish sentiment in the later years. In 2026, the expected average price is $5.49 with a max of $7.43 and a min of $4.07, yielding 0% ROI and neutral sentiment.
From 2027 onward the average price climbs to $6.25 (max $8.79, min $4.76) with a 13.8% ROI and neutral sentiment, followed by higher averages in 2028 ($6.64; max $9.79; min $4.86; ROI 20.9%; bullish) and 2029 ($8.11; max $12.41; min $5.74; ROI 47.7%; bullish). By 2030 the average reaches $10.43 (max $16.47; min $7.16) with a 90% ROI and bullish sentiment.
The ascent continues through 2031–2035, with 2031 avg $11.68 (ROI 112.8%), 2032 avg $12.85 (ROI 134.1%), 2033 avg $13.19 (ROI 140.3%), 2034 avg $13.64 (ROI 148.5%), and 2035 avg $14.28 (ROI 160.2%), all marked bullish. In 2040 the average price is projected at $24.64 (max $46.96; min $13.40) with a 348.8% ROI and bullish sentiment, and by 2050 the average is $53.86 (max $114.61; min $24.24) with an 881.1% ROI and bullish sentiment.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $10.43, a high of $16.47, and a low of $7.16, with an estimated ROI of 90% and bullish sentiment.
The forecast shows a bullish trajectory in later years with averages rising to $53.86 by 2050 and an upside of up to 881.1% in the max case, though near-term years vary (e.g., 2026 avg $5.49 with 0% ROI and neutral sentiment). These are estimates and not guarantees.
Yes, the maximum forecast price by 2050 is $114.61, with an average of $53.86, indicating the potential to exceed $100 in the long-term under the provided scenario.
The 30-day range is $4.27 to $7.07.
The current price is $5.49 and the market cap is $1.58B.
Taysha Gene Therapies, Inc. Community Discussion
0Share your Taysha Gene Therapies, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.